logo
  • Home
  • Technologies
    • Live Cell Encapsulation
    • Research & Development
    • Cancer
    • Diabetes
    • Cannabinoids
  • Company
    • Management
    • Board of Directors
    • Governance
    • Medical and Scientific Advisory Board
    • International Diabetes Consortium
  • Investor Relations
    • Overview
    • News / Events
    • Shareholder Calls / Presentations
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • News
    • Press Releases
    • Articles
    • Reports
    • Media
    • Photo Gallery
  • Contact

Press Releases

Navigation Toggle Navigation
  • Overview
  • News / Events
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Shareholder Calls / Presentations
  • Company Information
  • Financial Information
  • Stock Data
  • SEC Filings
  • Corporate Governance
  • Quick Links
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
  • All News
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • Apr 3, 2017

PharmaCyte Biotech Appoints Dr. Mark Rabe Director of Cannabis Program Development

  • Mar 22, 2017

PharmaCyte Biotech Strengthens Protection of Cancer Therapy with Patent Filing

  • Mar 17, 2017

PharmaCyte Biotech CEO Addresses IND Submission Questions

  • Mar 13, 2017

PharmaCyte Biotech Names Dr. Leonard Makowka as Senior Strategic Advisor

  • Feb 23, 2017

First Ever Cannabis-Based ETF to Include PharmaCyte Biotech, Abbott Laboratories, and GW Pharmaceuticals

  • Feb 21, 2017

PharmaCyte Biotech Discusses Patient Enrollment and TD2’s Role in Upcoming Clinical Trial

  • Feb 13, 2017

PharmaCyte Biotech Moves Closer to Filing IND with Naming of Comparator Arm for Upcoming Clinical Trial and Discusses Pivotal Trial Opportunity

  • Feb 8, 2017

PharmaCyte Biotech Releases Shareholder Call and Complete Q&A Playback Information

  • Feb 2, 2017

PharmaCyte Biotech Provides Update for February 7th Shareholder Call

  • Jan 30, 2017

PharmaCyte Biotech Retains Facet Life Sciences to Guide Pancreatic Cancer Therapy Development Lifecycle with FDA

RSS
  • « Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...19
  • Next »

Contact Us

PharmaCyte Biotech, Inc.
23046 Avenida de la Carlota, Suite 600
Laguna Hills, California 92653
Office Number: 917.595.2850
Facsimile Number: 917.595.2851
Email: info@PharmaCyte.com

Latest News

  • PharmaCyte Biotech Releases CEO Interview from The Big Biz Show January 22, 2019
  • PharmaCyte Biotech’s CEO Interviewing Live on The Big Biz Show January 17, 2019